Francois Rochon
Giverny Capital
Francois Rochon Eli Lilly and Company stake
total: 126
Giverny Capital LLY trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q3
- Held for:
- 9 quarters
- Latest activity:
- 2022 Q4
According to 2026 Q2 report, Francois Rochon doesn't hold any Eli Lilly and Company (LLY) shares. To date, the estimated cost basis is nearly $148.15 for "buy" trades and estimated average "sell" price is $324.07. Giverny Capital first purchased LLY in 2020 Q3, initially acquiring 432 shares. Since the initial investment in Eli Lilly and Company (LLY), Giverny Capital has made 1 more transaction.
When did Francois Rochon sell Eli Lilly and Company (LLY)?
Francois Rochon sold off the entire Eli Lilly and Company (LLY) position in 2022 Q4.
When did Francois Rochon buy Eli Lilly and Company (LLY)?
Francois Rochon first invested in Eli Lilly and Company (LLY) in 2020 Q3 at the reported quarter-end price of $148.15 per share.
What's the cost basis of Giverny Capital's LLY stake?
The estimated cost basis for Eli Lilly and Company (LLY) stake is around $148.15 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $148.15
- Weighted AVG sell price:
- $324.07
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.